Skip to main content

Zantac lawsuit drop ‘not as significant as it appears’ for GSK stock, analysts say

The withdrawal of a plaintiff in GSK's first Zantac lawsuit but may not be “as significant as it appears”, say analysts from RBC Europe.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.